🇺🇸 AMGN — Amgen Inc.

Salud Mantener
← Volver

Precio actual

460,42 USD

Máx. histórico

478,48

2 días

Split 2:1 del 22/11/1999

Caída desde máximo

-3,77%

Rango 52 semanas

312,39 – 483,99

Variación hoy

+0,03%

Cierre anterior

460,28

Rango de hoy

447,04 – 462,91

Volumen hoy

2.578.799

Peor caída histórica

-78,03%

17/06/1983 → 19/11/1984

Recuperado en 487 días

Volatilidad anualizada ⓘ

37,46%

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
26,69 (puede no estar actualizado)
Dividend yield
2,19% (puede no estar actualizado)
Precio objetivo analistas
409,63 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 1 hora
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,16%
Fecha de pago Importe por participación
21/08/2026 2,5200 USD
15/05/2026 2,5200 USD
13/02/2026 2,5200 USD
21/11/2025 2,3800 USD
22/08/2025 2,3800 USD
16/05/2025 2,3800 USD
14/02/2025 2,3800 USD
18/11/2024 2,2500 USD
16/08/2024 2,2500 USD
16/05/2024 2,2500 USD
15/02/2024 2,2500 USD
16/11/2023 2,1300 USD
17/08/2023 2,1300 USD
17/05/2023 2,1300 USD
14/02/2023 2,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
29/08/2017 170,66 172,35 170,35 172,23 +0,26% 1,17% 1.483.000
28/08/2017 170,86 172,64 170,26 171,78 +1,20% 1,39% 2.359.500
25/08/2017 170,82 171,57 169,40 169,74 -0,12% 1,27% 1.510.800
24/08/2017 169,28 170,69 168,57 169,95 +0,56% 1,25% 1.922.400
23/08/2017 169,66 169,94 168,76 169,00 -0,63% 0,70% 1.279.400
22/08/2017 168,86 170,94 168,83 170,07 +1,14% 1,25% 1.933.500
21/08/2017 167,46 168,64 167,01 168,16 +0,52% 0,97% 1.533.300
18/08/2017 167,37 168,43 166,52 167,29 -0,31% 1,14% 1.741.900
17/08/2017 170,69 171,00 167,80 167,81 -2,09% 1,87% 2.630.600
16/08/2017 170,26 172,64 170,14 171,39 +0,79% 1,47% 1.618.800
15/08/2017 171,10 171,45 169,76 170,04 -0,95% 0,99% 1.956.300
14/08/2017 170,28 172,08 169,97 171,67 +1,32% 1,24% 1.915.800
11/08/2017 169,82 170,63 168,76 169,43 +0,19% 1,10% 1.571.600
10/08/2017 172,07 172,67 168,59 169,11 -2,56% 2,37% 3.443.800
09/08/2017 173,10 174,18 172,65 173,55 -0,08% 0,88% 1.972.200
08/08/2017 173,96 174,90 172,98 173,69 -0,51% 1,10% 2.325.200
07/08/2017 173,87 174,65 173,26 174,58 +0,42% 0,80% 1.193.800
04/08/2017 174,27 174,82 172,90 173,85 -0,19% 1,10% 1.915.600
03/08/2017 173,52 174,71 173,26 174,18 -0,16% 0,84% 1.725.900
02/08/2017 173,57 174,59 173,21 174,46 +0,19% 0,80% 2.209.200
01/08/2017 174,81 175,11 173,66 174,13 -0,22% 0,83% 2.069.600
31/07/2017 174,51 176,79 174,25 174,51 -0,02% 1,46% 2.424.800
28/07/2017 171,98 175,06 171,71 174,54 +1,39% 1,95% 2.463.500
27/07/2017 175,00 175,48 170,53 172,15 -2,13% 2,83% 5.523.200
26/07/2017 176,01 178,86 175,20 175,89 -2,76% 2,08% 5.446.100
25/07/2017 182,05 182,60 180,34 180,89 -0,09% 1,24% 3.343.200
24/07/2017 180,19 181,46 178,66 181,06 +0,47% 1,55% 2.503.100
21/07/2017 179,26 180,55 179,16 180,21 +0,50% 0,78% 2.674.700
20/07/2017 179,05 180,73 178,88 179,32 +0,08% 1,03% 3.039.300
19/07/2017 178,10 179,20 176,52 179,18 +0,96% 1,50% 2.440.700